Predict your next investment

HEALTHCARE | Biotechnology
archtherapeutics.com

See what CB Insights has to offer

Stage

Loan | IPO

Total Raised

$250K

Market Cap

0.02B

Stock Price

0.11

About Arch Therapeutics

Arch Therapeutics is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant), and manage wounds during surgery, trauma, and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's development stage product candidates include AC5 Advanced Wound System, AC5 Topical Hemostat, AC5-G, and AC5 Surgical Hemostat.1, 2

Arch Therapeutics Headquarter Location

235 Walnut Street Suite 6

Framingham, Massachusetts, 01702,

United States

855-340-2784

Latest Arch Therapeutics News

Arch Therapeutics Partners With Lovell Government Services To Expand Distribution Capabilities

Sep 2, 2021

Arch Therapeutics Partners With Lovell Government Services To Expand Distribution Capabilities FRAMINGHAM, Mass., Sept. Sep 2, 2021 7:00 AM EDT FRAMINGHAM, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (" Arch" or the " Company"), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced that it has entered into a non-exclusive distribution agreement with Lovell Government Services ("LGS"), a Service-Disabled Veteran-Owned Small Business ("SDVOSB"), to support and drive sales through the Veteran's Affairs hospitals and other governmental medical facilities. The partnership is intended to result in the inclusion of the Company's AC5 ® Advanced Wound System on targeted federal supply schedules. Simultaneous with this announcement, the Company and Buffalo Supply, Inc. ("Buffalo Supply") mutually agreed to terminate the existing exclusive distribution agreement entered into last year. "Partnering with an SDVOSB, especially one with the reputation of LGS, to drive distribution into the government is intended to provide several strategic advantages, most notably speed to market and enhanced access to multiple government contracting channels," stated Dan Yrigoyen, Vice President of Sales for Arch Therapeutics. "We thank Buffalo Supply for their past support and work done to date. Our new SDVOSB partnership is an exciting next step in our progress, and it represents an important element of our overall commercialization strategy," concluded Mr. Yrigoyen. "Lovell is excited to bring the healing power of Arch Therapeutics' technology to the Veterans and Department of Defense Hospital Systems," says Chris Lovell, CEO and Founder of Lovell Government Services. LGS partners with medical and pharmaceutical companies looking to better serve military and veteran patient populations. With this partnership, Federal, State, and Local Government Agencies can place their order for AC5 ® Advanced Wound System through appropriate contract vehicles while meeting their SDVOSB procurement goals. About Arch Therapeutics, Inc.Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5 ® Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G, AC5-V and AC5 Surgical Hemostat, among others. 1 , 2 _______________ 1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use. 2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries. About Lovell Government ServicesLovell Government Services was established by Chris Lovell, Major USMC Retired, in 2013. Lovell's mission is to serve the Veterans Administration (VA) Hospital System, the U.S. Military Medical Networks, other Federal Healthcare Systems, and the communities they support. Lovell is a certified Service-Disabled Veteran-Owned Small Business (SDVOSB) and ECAT, FSS, DAPA, and GSA contract holder. Lovell partners with Medical and Pharmaceutical Suppliers to fast track and distribute the latest in life-saving technologies to the Federal Government as their Federal Vendor. Lovell Government Services helps companies win government contracts and government sales. Learn more at  www.lovellgov.com . Notice Regarding Forward-Looking StatementsThis news release contains "forward-looking statements" as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our ability to recruit additional field sales representatives and their effectiveness, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to obtain the inclusion of our AC5 ® Advanced Wound System on targeted federal supply schedules, our ability to develop and commercialize products based on our technology platform, and market conditions, and our ability to establish additional commercialization partnerships and build a critical mass of field sales representatives. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov . Contact:ARTH Investor RelationsToll Free: +1-855-340-ARTH (2784) (US and Canada)Email: investors@archtherapeutics.com Website: www.archtherapeutics.com or

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Arch Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Arch Therapeutics is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

10,433 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. Excludes CDMOs/CMOs. *Columns updated as regularly as possible.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Arch Therapeutics Patents

Arch Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Oncology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/13/2018

8/10/2021

Transcription factors, Clusters of differentiation, Oncology, Proteins, Immune system

Grant

Application Date

9/13/2018

Grant Date

8/10/2021

Title

Related Topics

Transcription factors, Clusters of differentiation, Oncology, Proteins, Immune system

Status

Grant

Arch Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Arch Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.